Coenzyme Q10: Uses, Efficacy, Benefits, and Considerations

1) Conditions Studied for Coenzyme Q10 Use

Coenzyme Q10 has been studied for a variety of conditions, including:

• Heart failure and heart disease
• Hypertension (high blood pressure)
• Migraines
• Neurological disorders such as Parkinson's disease
• Diabetes
• Muscle weakness associated with certain medications (statin-induced myopathy)
• Cancer
• Fibromyalgia

2) Efficacy in Treating These Conditions

Research on the effectiveness of Coenzyme Q10 in treating these conditions has produced mixed results:

• In some studies, Coenzyme Q10 has been shown to benefit heart failure patients, but more research is needed.
• It may help lower blood pressure slightly, but it is not a substitute for blood pressure medication.
• It has shown promise in reducing the frequency of migraines in some people.
• While some early research suggested potential benefits for neurological conditions, current evidence is insufficient to support its use for Parkinson's disease and similar disorders.
• Its role in diabetes management is unclear and requires more research.
• Coenzyme Q10 supplements may reduce muscle pain associated with statin use, but evidence is not conclusive.
• There is no strong evidence supporting its use for cancer or fibromyalgia.

3) Health Benefits of Coenzyme Q10

Coenzyme Q10 is known for its potential health benefits, such as:

• Acting as an antioxidant and protecting cells from damage
• Improving energy production in cells
• Possibly improving symptoms and quality of life in heart failure patients
• Reducing the severity and frequency of migraines
• May help with fertility by improving sperm motility in men and possibly reversing age-related decline in egg quality and quantity in women

4) Downsides of Coenzyme Q10

While Coenzyme Q10 is generally well-tolerated, there are some potential downsides:

• It can cause mild side effects such as stomach upset, loss of appetite, nausea, vomiting, and diarrhea.
• It may interact with certain medications, including blood thinners and chemotherapy drugs.
• High doses can lead to insomnia, increased liver enzymes, dizziness, and light sensitivity.
• It can be expensive and is not always covered by insurance.

5) Coenzyme Q10 and Genetic Variations

There is some evidence that genetic variations may influence the effect of Coenzyme Q10:

• Individuals with certain genetic mutations may not synthesize Coenzyme Q10 efficiently and could potentially benefit from supplementation.
• More research is needed to fully understand the impact of genetic variations on the efficacy of Coenzyme Q10 supplements.
• It's important to consult with a healthcare provider before starting any supplement, especially if you have known genetic conditions that may affect supplement metabolism.

Coenzyme Q10 in Health and Disease

Role of Coenzyme Q10 in Cellular Energy and Antioxidant Defense

Coenzyme Q10 (CoQ10), also known as ubiquinone, plays a significant role in the generation of cellular energy and serves as an important antioxidant. It is synthesized in the human body with the aid of several vitamins and is found in various foods, most abundantly in meat and fish. CoQ10 is present in the mitochondrial respiratory chain and is essential for ATP production.

Coenzyme Q10 Deficiency and Disease Link

Deficiencies in CoQ10 have been associated with various forms of cancer, cardiovascular diseases, and neurological disorders. CoQ10 levels are observed to be lower in patients with conditions such as fibromyalgia and chronic fatigue syndrome, suggesting a potential role in disease pathophysiology.

Treatment of Neurological Disorders

Clinical trials have explored the use of CoQ10 in neurological diseases, such as Parkinson's disease and Huntington's disease, where its antioxidant properties and mitochondrial support may offer therapeutic benefits.

Coenzyme Q10 and Aging

CoQ10 has been linked to the aging process, with its redox status potentially serving as a marker for oxidative stress associated with aging.

Coenzyme Q10 Supplementation

Supplementation with CoQ10 has shown promise in improving clinical symptoms in conditions like fibromyalgia, improving sperm motility in cases of male infertility, and reducing the severity of migraine headaches. It has also been considered as a treatment option for statin-associated muscle symptoms, though evidence is inconsistent.

Safety and Dosage of Coenzyme Q10

CoQ10 supplementation is generally considered safe, with clinical trials testing doses up to 3000 mg/day in adults without significant adverse effects. However, optimal dosing and long-term safety require further investigation.

References:

1. Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy
2. Improvement of coenzyme Q10 production: mutagenesis induced by high hydrostatic pressure treatment and optimization of fermentation conditions
3. Coenzyme Q10 contents in foods and fortification strategies
4. The distribution and content of ubiquinone in foods
5. Fatty acid composition and antioxidant levels in muscle tissue of different Mediterranean marine species of fish and shellfish
6. Coenzyme Q10 in the diet--daily intake and relative bioavailability
7. Quantitative determination of coenyzme Q10 by liquid chromatography and liquid chromatography/mass spectrometry in dairy products
8. The coenzyme Q10 content of the average Danish diet
9. Production of ubiquinone-10 using bacteria
10. Current prospects for the production of coenzyme Q10 in microbes
11. Biotechnological production and applications of coenzyme Q10
12. Optimization of culture conditions and scale-up to pilot and plant scales for coenzyme Q10 production by Agrobacterium tumefaciens
13. Ubiquinone-10 production using Agrobacterium tumefaciens dps gene in Escherichia coli by coexpression system
14. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics
15. The biochemical, pathophysiological, and medical aspects of ubiquinone function
16. Coenzyme Q10 in neuromuscular and neurodegenerative disorders
17. Bioavailability enhancement of coenzyme Q10: an extensive review of patents
18. Regulation of the mevalonate pathway
19. Coenzyme Q--biosynthesis and functions
20. Effect of squalestatin 1 on the biosynthesis of the mevalonate pathway lipids
21. Squalene synthase inhibition alters metabolism of nonsterols in rat liver
22. Age-related changes in the lipid compositions of rat and human tissues
23. Biochemical, physiological and medical aspects of ubiquinone function
24. Coenzyme Q10
25. Uptake of dietary coenzyme Q supplement is limited in rats
26. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells
27. Characterization of cellular uptake and distribution of coenzyme Q10 and vitamin E in PC12 cells
28. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of alpha-tocopherol into rat organs and cells
30. Distribution and breakdown of labeled coenzyme Q10 in rat
31. Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults
32. The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity
33. Similar therapeutic serum levels attained with emulsified and oil-based preparations of coenzyme Q10
34. Relative bioavailability of coenzyme Q10 formulations in human subjects
35. Antioxidative effect of dietary coenzyme Q10 in human blood plasma
36. A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period
37. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations
38. Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets
39. Safety assessment of PureSorb-Q40 in healthy subjects and serum coenzyme Q10 level in excessive dosing
40. Comparison of uptake between PureSorb-Q40 and regular hydrophobic coenzyme Q10 in rats and humans after single oral intake
41. A 91-d repeated dose oral toxicity study of PureSorb-Q(TM)40 in rats
42. Serum and muscle tissue ubiquinone levels in healthy subjects
43. Distribution and redox state of ubiquinones in rat and human tissues
44. Coenzyme Q, oxidative stress and aging
45. Effects of coenzyme Q10 and alpha-tocopherol administration on their tissue levels in the mouse: elevation of mitochondrial alpha-tocopherol by coenzyme Q10
46. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
47. Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat
48. Coenzyme Q intake elevates the mitochondrial and tissue levels of Coenzyme Q and alpha-tocopherol in young mice
49. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage
50. The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline
51. Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein
52. Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes
53. Effect of ubidecarenone on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats
54. [Interaction between warfarin and coenzyme Q10]
55. Reduced effect of warfarin caused by ubidecarenone
56. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis
57. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial
58. Calorie restriction modifies ubiquinone and COQ transcript levels in mouse tissues
59. Mitochondrial coenzyme Q content and aging
60. Proton leak and hydrogen peroxide production in liver mitochondria from energy-restricted rats
61. Effect of age and caloric restriction on coenzyme Q and alpha-tocopherol levels in the rat
62. Mitochondrial dysfunctions during aging: vitamin E deficiency or caloric restriction--two different ways of modulating stress
63. Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation
64. Extension of life-span in Caenorhabditis elegans by a diet lacking coenzyme Q
65. Silencing of ubiquinone biosynthesis genes extends life span in Caenorhabditis elegans
66. clk-1, mitochondria, and physiological rates
67. Altered bacterial metabolism, not coenzyme Q content, is responsible for the lifespan extension in Caenorhabditis elegans fed an Escherichia coli diet lacking coenzyme Q
68. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice
69. The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice
70. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice
71. Prolonged intake of coenzyme Q10 impairs cognitive functions in mice
72. Coenzyme Q(10) supplementation reverses age-related impairments in spatial learning and lowers protein oxidation
73. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein
74. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases
75. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases
76. Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine
77. Neuroprotective effects of creatine
78. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness
79. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness
80. Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats
81. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression
82. Open label trial of coenzyme Q10 as a migraine preventive
83. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial
84. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine
85. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue
86. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10
87. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10
88. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity
89. Lack of effect of coenzyme q10 on doxorubicin cytotoxicity in breast cancer cell cultures
90. Effect of coenzyme Q10 on the disposition of doxorubicin in rats
91. Effect of coenzyme-q10 on Doxorubicin-induced nephrotoxicity in rats
92. Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats
93. Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy
94. Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines
95. Coenzyme Q10: an independent predictor of mortality in chronic heart failure
96. Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese
97. Chronic administration of coenzyme Q10 limits postinfarct myocardial remodeling in rats
98. Clinical aspects of coenzyme Q10: an update
99. Coenzyme Q10 and cardiovascular disease: a review
100. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction
101. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction
102. The effect of coenzyme Q10 in patients with congestive heart failure
103. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction
104. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy
105. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group
106. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM)
107. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens
108. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study
109. Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species
110. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation
111. NO/redox disequilibrium in the failing heart and cardiovascular system
112. Extracellular superoxide dismutase and cardiovascular disease
113. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients
114. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus
115. Coenzyme Q10 and exercise training in chronic heart failure
116. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study
117. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials
118. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension
119. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome
120. Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension
121. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study
122. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress
123. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress
124. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis
125. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways
126. Coenzyme Q10 suppresses oxLDL-induced endothelial oxidative injuries by the modulation of LOX-1-mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway
127. Nitrosation and oxidation in the regulation of gene expression
128. Functions of coenzyme Q10 in inflammation and gene expression
129. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease
130. Plasma levels of antioxidant vitamins and oxidative stress in patients with acute myocardial infarction
131. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study
132. Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics?
133. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes
134. Effect of combination therapy with coenzyme Q10 on functional and metabolic parameters in patients with type 1 diabetes mellitus
135. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus
136. Antioxidants in the treatment of diabetes
137. HbA1c and serum levels of advanced glycation and oxidation protein products in poorly and well controlled children and adolescents with type 1 diabetes mellitus
138. Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes
139. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes
140. Amelioration of altered antioxidant enzymes activity and glomerulosclerosis by coenzyme Q10 in alloxan-induced diabetic rats
141. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes
142. Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model
143. Prophylactic and antinociceptive effects of coenzyme Q10 on diabetic neuropathic pain in a mouse model of type 1 diabetes
144. Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard
145. Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healthy children and adults
146. Muscle ubiquinone in healthy physically active males
147. A combination of lipoic acid plus coenzyme Q10 induces PGC1α, a master switch of energy metabolism, improves stress response, and increases cellular glutathione levels in cultured C2C12 skeletal muscle cells
148. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres
149. PGC-1alpha: a key regulator of energy metabolism
150. PGC-1alpha in aging and anti-aging interventions
151. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle
152. Fiber phenotype and coenzyme Q₁₀ content in Turkey skeletal muscles
153. Coenzyme Q10 deficiency in children: frequent type 2C muscle fibers with normal morphology
154. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins
155. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals
156. Coenzyme Q10 supplementation and exercise-induced oxidative stress in humans
157. Impact of oral ubiquinol on blood oxidative stress and exercise performance
158. Muscle and plasma coenzyme Q10 concentration, aerobic power and exercise economy of healthy men in response to four weeks of supplementation
159. The effects of coenzyme Q10 supplementation on performance during repeated bouts of supramaximal exercise in sedentary men
160. Oxidative stress and antioxidant defense in plasma after repeated bouts of supramaximal exercise: the effect of coenzyme Q10
161. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance
162. Antifatigue effects of coenzyme Q10 during physical fatigue
163. Effect of Coenzyme Q10 supplementation on exercise-induced muscular injury of rats
164. The effect of Coenzyme Q10 on reperfusion injury in canine myocardium
165. Mechanism responsible for endotoxin-induced lung microsomal dysfunction in rats
166. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10
167. Influence of CoQ10 on autonomic nervous activity and energy metabolism during exercise in healthy subjects
168. Antifatigue effect of coenzyme Q10 in mice
169. Mitochondrial nutrients stimulate performance and mitochondrial biogenesis in exhaustively exercised rats
170. A randomized trial of coenzyme Q10 in mitochondrial disorders
171. Biochemical functions of coenzyme Q10
172. Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle
173. Metabolism and function of coenzyme Q
174. The antioxidant role of coenzyme Q
175. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles
176. Stopped-flow kinetic study of the regeneration reaction of tocopheroxyl radical by reduced ubiquinone-10 in solution
177. Endogenous ubiquinol prevents protein modification accompanying lipid peroxidation in beef heart submitochondrial particles
178. Oxidative modification of nicotinamide nucleotide transhydrogenase in submitochondrial particles: effect of endogenous ubiquinol
179. Nrf2, a guardian of healthspan and gatekeeper of species longevity
180. Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress
181. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation
182. Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta1 expression
183. Redox status of coenzyme Q10 is associated with chronological age
184. Hydrogen peroxide production by mitochondria may be a biomarker of aging
185. Aging: a theory based on free radical and radiation chemistry
186. Electron paramagnetic resonance (EPR) imaging in skin: biophysical and biochemical microscopy
187. Redox regulation of transcriptional activators
188. Inflammation and oxidative stress in carcinogenesis
189. Oxidants as stimulators of signal transduction
190. Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin
191. UV-irradiation depletes antioxidants and causes oxidative damage in a model of human skin
192. Coenzyme Q10, a cutaneous antioxidant and energizer
193. Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease
194. Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease
195. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients
196. Aging skin is functionally anaerobic: importance of coenzyme Q10 for anti aging skin care
197. Biochemical rationale and experimental data on the antiaging properties of CoQ(10) at skin level
198. Coenzyme Q(10) enhances dermal elastin expression, inhibits IL-1α production and melanin synthesis in vitro
199. Mechanisms of inhibitory effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo
200. Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects
201. Safety and efficacy of antioxidants-loaded nanoparticles for an anti-aging application
202. Effect of coenzyme Q10 on cutaneous healing in skin-incised mice
203. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease
204. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q₁₀ effect on clinical improvement
205. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia
206. Coenzyme Q10 in salivary cells correlate with blood cells in Fibromyalgia: improvement in clinical and biochemical parameter after oral treatment
207. Oxidative stress and mitochondrial dysfunction in fibromyalgia
208. Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient
209. Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients
210. Can coenzyme q10 improve clinical and molecular parameters in fibromyalgia?
211. Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation
212. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment
213. Carnitine and coenzyme Q10 levels in individuals with Prader-Willi syndrome
214. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10
215. Nutritional strategies for treating chronic fatigue syndrome
216. Prospective observational study of treatments for unexplained chronic fatigue
217. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder
218. The assessment of the energy metabolism in patients with chronic fatigue syndrome by serum fluorescence emission
219. Seminal antioxidants in humans: preoperative and postoperative evaluation of coenzyme Q10 in varicocele patients
220. Coenzyme Q10 and male infertility
221. Coenzyme Q(10) in male infertility: physiopathology and therapy
222. Total oxyradical scavenging capacity toward different reactive oxygen species in seminal plasma and sperm cells
223. Generation of reactive oxygen species, lipid peroxidation, and human sperm function
224. New insights into sperm physiology and pathology
225. Free radical theory of aging: implications in male infertility
226. The mammalian spermatozoon
227. Nonaprenyl-4-hydroxybenzoate transferase, an enzyme involved in ubiquinone biosynthesis, in the endoplasmic reticulum-Golgi system of rat liver
228. Analysis of sperm movement in relation to the oxidative stress created by leukocytes in washed sperm preparations and seminal plasma
229. Antioxidant treatment for male subfertility: a promise that remains unfulfilled
230. Effect of daily spermatozoan production but not age on transit time of spermatozoa through the human epididymis
231. Leukocytospermia is associated with poor semen quality
232. Coenzyme Q10: another biochemical alteration linked to infertility in varicocele patients?
233. Effects of testosterone on antioxidant systems in male secondary hypogonadism
234. Evaluation of antioxidant systems in pituitary-adrenal axis diseases
235. Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study
236. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial
237. Coenzyme Q: potentially useful index of bioenergetic and oxidative status of spermatozoa
238. Relationship between sperm cell ubiquinone and seminal parameters in subjects with and without varicocele
239. Pathophysiology of varicoceles in male infertility
240. The effect of coenzyme Q10 on sperm motility and function
241. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men
242. Peyronie's disease
243. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984
244. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study
245. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies
246. Carnitine and coenzyme Q10: biochemical properties and functions, synergism and complementary action
247. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy
248. Mitochondrial biogenesis during skeletal muscle regeneration
249. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1
250. Influence of physical exercise on polyamine synthesis in the rat skeletal muscle
251. Polyamines, androgens, and skeletal muscle hypertrophy
252. Mevalonate pathway: a review of clinical and therapeutical implications
253. Effect of microbial fermentation on content of statin, GABA, and polyphenols in Pu-Erh tea
254. Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation
255. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study
256. The effects of CoQ10 supplements on patients taking statin drugs
257. [Reduced synthesis of coenzyme Q10 may cause statin related myopathy]
258. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction
259. Statin intolerance: now a solved problem
260. Evidence-based management of statin myopathy
261. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia?
262. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease
263. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein
264. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux
265. Investigation of Pycnogenol® in combination with coenzymeQ10 in heart failure patients (NYHA II/III)
266. Safety assessment of coenzyme Q10 (CoQ10)
267. The role of coenzyme Q10 in statin-associated myopathy: a systematic review
268. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials
269. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure
270. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS
271. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
272. Clinical trials of coenzyme Q10 in neurological disorders
273. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!